Clinical trial
Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
NCT01193244
Study timeline
Study start (actual)2010-10-01Date precision: day
Registry last updated2017-05-17
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Prostate Cancerunresolved
Interventions
Sponsors & collaborators
Millennium Pharmaceuticals, Inc.lead sponsor
Mapped research locations
New YorkNew York, United States1BostonMassachusetts, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1BaltimoreMaryland, United States1TorontoOntario, Canada1NashvilleTennessee, United States1San FranciscoCalifornia, United States1MadridSpain1BarcelonaSpain1LondonUnited Kingdom1ParisFrance1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01193244 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.